Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol
Sponsor: Beth Israel Medical Center
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Beth Israel Medical Center
Other Metastatic Pancreatic Adenocarcinoma trials with similar outcome
Listed as NCT01760252, this PHASE2 trial focuses on Metastatic Pancreatic Adenocarcinoma and remains terminated or withdrawn. Sponsored by Beth Israel Medical Center, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Medical Center
- St. Luke's-Roosevelt Hospital Center
For direct contact, visit the study record on ClinicalTrials.gov .